Pharsight

Spes Pharms patents expiration

1. Focinvez patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11065256 SPES PHARMS Administration and dosage of diaminophenothiazines
Jan, 2039

(14 years from now)

Drugs and Companies using FOSAPREPITANT DIMEGLUMINE ingredient

Market Authorisation Date: 22 August, 2023

Treatment: NA

Dosage: SOLUTION;INTRAVENOUS

More Information on Dosage

FOCINVEZ family patents

Family Patents